Hey and Kimmelman • The Risk-Escalation Model Spencer Phillips Hey and Jonathan Kimmelman The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials - Aliskiren amlodipine - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-07-03 12:23:08 Clinical pharmacology Clinical research Design of experiments Epidemiology Medical terminology Clinical trial Therapeutic index Adverse effect Chemotherapy Amyotrophic lateral sclerosis Experimental cancer treatment		Hey and Kimmelman • The Risk-Escalation Model Spencer Phillips Hey and Jonathan Kimmelman The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials Add to Reading List Source URL: kiej.georgetown.edu Download Document from Source Website File Size: 1,70 MB Share Document on Facebook

	Amyotrophic lateral sclerosis (ALS) is a chronic relentless neurodegenerative disorder and it is the most common motor neuron disorder of the adult life DocID: 1sGJy - View Document
	New NIH guidelines to improve Experimental Rigor and Reproducibility Oswald Steward Professor, Department of Anatomy & Neurobiology Senior Associate Dean for Research University of California School of Medicine DocID: 1rjyT - View Document
	................................... OCCUPATIONAL Therapy Overcome your limitations. DocID: 1qQof - View Document
	Caffeic acid phenethyl ester extends survival of a mouse model of amyotrophic lateral sclerosis DocID: 1qMIa - View Document
	Sarah Ayer 311 Thornton Drive Franklin, TX0000 January 31, 1999 David McMurrey DocID: 1qFos - View Document